PE20150883A1 - Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso - Google Patents
Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su usoInfo
- Publication number
- PE20150883A1 PE20150883A1 PE2015000583A PE2015000583A PE20150883A1 PE 20150883 A1 PE20150883 A1 PE 20150883A1 PE 2015000583 A PE2015000583 A PE 2015000583A PE 2015000583 A PE2015000583 A PE 2015000583A PE 20150883 A1 PE20150883 A1 PE 20150883A1
- Authority
- PE
- Peru
- Prior art keywords
- imidazo
- pyridine carboxamides
- amine substitutes
- prevention
- treatment
- Prior art date
Links
- -1 IMIDAZO [1,2-A] PYRIDINE CARBOXAMIDES AMINE Chemical class 0.000 title 1
- 230000006806 disease prevention Effects 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- ZMBYQTGAXZOMOO-UHFFFAOYSA-N imidazo[1,2-a]pyridine-3-carboxamide Chemical class C1=CC=CN2C(C(=O)N)=CN=C21 ZMBYQTGAXZOMOO-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Referida a derivados de imidazo[1,2-a]piridin-3-carboxamidas sustituidas de formula (I), a procedimientos para su preparacion, a su uso solas o en combinaciones para el tratamiento y/o la prevencion de enfermedades y a su uso para la preparacion de medicamentos para el tratamiento y/o la prevencion de enfermedades, en especial para el tratamiento y/o la prevencion de enfermedades cardiovasculares
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12191201 | 2012-11-05 | ||
| US13/789,655 US9126998B2 (en) | 2012-11-05 | 2013-03-07 | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
| EP13178248 | 2013-07-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20150883A1 true PE20150883A1 (es) | 2015-05-27 |
Family
ID=50626532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015000583A PE20150883A1 (es) | 2012-11-05 | 2013-11-04 | Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso |
Country Status (41)
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9624214B2 (en) | 2012-11-05 | 2017-04-18 | Bayer Pharma Aktiengesellschaft | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
| US8778964B2 (en) * | 2012-11-05 | 2014-07-15 | Bayer Pharma Aktiengesellschaft | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use |
| US9126998B2 (en) | 2012-11-05 | 2015-09-08 | Bayer Pharma AG | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
| CA2914100A1 (en) | 2013-06-04 | 2014-12-11 | Bayer Pharma Aktiengesellschaft | 3-aryl-substituted imidazo[1,2-a]pyridines and the use thereof |
| WO2015106268A1 (en) | 2014-01-13 | 2015-07-16 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
| US9688699B2 (en) | 2014-02-19 | 2017-06-27 | Bayer Pharma Aktiengesellschaft | 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines |
| CA2943005A1 (en) * | 2014-03-21 | 2015-09-24 | Bayer Pharma Aktiengesellschaft | Cyano-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
| EP3137465A1 (de) * | 2014-05-02 | 2017-03-08 | Bayer Pharma Aktiengesellschaft | 6-chlor-substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung als stimulatoren der löslichen guanylatcyclase |
| CA2947387A1 (en) * | 2014-05-02 | 2015-11-05 | Bayer Pharma Aktiengesellschaft | Imidazo[1,2-a]pyridines as soluble guanylate cyclase stimulators for the treatment of cardiovascular diseases |
| JP2017537922A (ja) * | 2014-12-02 | 2017-12-21 | バイエル・ファルマ・アクティエンゲゼルシャフト | 置換ピラゾロ［１，５−ａ］ピリジンおよびイミダゾ［１，２−ａ］ピラジンならびにそれらの使用 |
| CA2969268A1 (en) | 2014-12-02 | 2016-06-09 | Bayer Pharma Aktiengesellschaft | Heteroaryl-substituted imidazo[1,2-a]pyridines and their use |
| JP2018505886A (ja) * | 2015-02-05 | 2018-03-01 | バイエル・ファルマ・アクティエンゲゼルシャフト | 心血管疾患を治療するための可溶性グアニル酸シクラーゼ（ＳＧＣ）の刺激物質としてのＮ−置換８−［（２，６−ジフルオロベンジル）オキシ］−２，６−ジメチルイミダゾ［１，２−ａ］ピラジン−３−カルボキサミド誘導体 |
| US10214526B2 (en) * | 2015-02-05 | 2019-02-26 | Bayer Pharma Aktiengesellschaft | Substituted pyrazolo[1,5-a]-pyridine-3-carboxamides and use thereof |
| AU2016258847A1 (en) | 2015-05-06 | 2017-11-16 | Bayer Pharma Aktiengesellschaft | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of Digital Ulcers (DU) concomitant to Systemic Sclerosis (SSc) |
| WO2016198691A1 (en) | 2015-06-11 | 2016-12-15 | Basilea Pharmaceutica Ag | Efflux-pump inhibitors and therapeutic uses thereof |
| WO2017013010A1 (de) | 2015-07-23 | 2017-01-26 | Bayer Pharma Aktiengesellschaft | Stimulatoren und/oder aktivatoren der löslichen guanylatzyklase (sgc) in kombination mit einem inhibitor der neutralen endopeptidase (nep inhibitor) und/oder einem angiotensin aii-antagonisten und ihre verwendung |
| CN108463224A (zh) | 2015-12-14 | 2018-08-28 | 铁木医药有限公司 | sGC刺激剂用于胃肠功能障碍治疗的应用 |
| JOP20170113B1 (ar) * | 2016-05-09 | 2023-03-28 | Bayer Pharma AG | مركبات 5، 6، 7، 8-رباعي هيدرو [1، 2، 4] تريازولو [4، 3-أ] بيريدين 3(2h)-ون مستبدلة ومركبات 2، 5، 6، 7-رباعي هيدرو-3h-بيرولو [2، 1-ج] [1، 2، 4] تريازول-3-ون واستخداماتها |
| MY199759A (en) | 2016-09-02 | 2023-11-21 | Tisento Therapeutics Inc | Fused bicyclic sgc stimulators |
| EP3525778A1 (de) | 2016-10-11 | 2019-08-21 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten |
| EP3525779B1 (de) | 2016-10-11 | 2024-06-05 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend den sgc stimulator vericuguat und den mineralcorticoid-rezeptor-antagonist finerenone |
| EP3554488A2 (en) | 2016-12-13 | 2019-10-23 | Cyclerion Therapeutics, Inc. | Use of sgc stimulators for the treatment of esophageal motility disorders |
| WO2018153899A1 (de) | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit stimulatoren und/oder aktivatoren der löslichen guanylatcyclase (sgc) |
| WO2018184976A1 (de) | 2017-04-05 | 2018-10-11 | Bayer Pharma Aktiengesellschaft | Substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung |
| WO2019081353A1 (de) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | Substituierte imidazopyridinamide und ihre verwendung |
| WO2019211081A1 (en) * | 2018-04-30 | 2019-11-07 | Bayer Aktiengesellschaft | The use of sgc activators and sgc stimulators for the treatment of cognitive impairment |
| EP3566704A1 (en) | 2018-05-11 | 2019-11-13 | Bayer Aktiengesellschaft | The use of non-steroidal mineralocorticoid receptor antagonists alone or in combination for the treatment of muscular or neuromuscular diseases |
| JOP20200287A1 (ar) | 2018-05-15 | 2020-11-09 | Bayer Ag | بنزاميدات مستبدلة بـ 3،1- ثيازول-2- يل للمعالجة من أمراض مصاحبة لتحسس الألياف العصبية |
| US11508483B2 (en) | 2018-05-30 | 2022-11-22 | Adverio Pharma Gmbh | Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group |
| US12220414B2 (en) | 2018-07-11 | 2025-02-11 | Tisento Therapeutics Inc. | Use of sGC stimulators for the treatment of mitochondrial disorders |
| WO2020164008A1 (en) | 2019-02-13 | 2020-08-20 | Bayer Aktiengesellschaft | Process for the preparation of porous microparticles |
| WO2020216669A1 (de) | 2019-04-23 | 2020-10-29 | Bayer Aktiengesellschaft | Phenylsubstituierte imidazopyridinamide und ihre verwendung |
| EP3822265A1 (en) | 2019-11-15 | 2021-05-19 | Bayer AG | Substituted hydantoinamides as adamts7 antagonists |
| EP3822268A1 (en) | 2019-11-15 | 2021-05-19 | Bayer Aktiengesellschaft | Substituted hydantoinamides as adamts7 antagonists |
| JP2023035862A (ja) * | 2021-08-30 | 2023-03-13 | Jnc株式会社 | シクロブタン環を有するジアミン誘導体、およびその塩 |
| EP4457215A1 (en) | 2021-12-29 | 2024-11-06 | Bayer Aktiengesellschaft | Process for preparing (5s)-{[2-(4-carboxyphenyl)ethyl] 2-(2-{ 3-chloro-4'-(trifluoromethyl)biphenyl-4- yl]methoxy}phenyl)ethyl]aminol-5,6,7,8-tetrahydroquinoline-2-carboxylic acid and its crystalline forms for use as pharmaceutically active compound |
| AU2022424376A1 (en) | 2021-12-29 | 2024-07-04 | Bayer Aktiengesellschaft | Treatment of cardiopulmonary disorders |
| WO2023126438A1 (en) | 2021-12-29 | 2023-07-06 | Bayer Aktiengesellschaft | Pharmaceutical dry powder inhalation formulation |
| WO2024102699A1 (en) * | 2022-11-07 | 2024-05-16 | ELANCO US, Inc. | Guanylate cyclase (gc) stimulator formulations and uses thereof |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0266890A1 (en) | 1986-10-07 | 1988-05-11 | Yamanouchi Pharmaceutical Co. Ltd. | Imidazopyridine derivatives, their production, and pharmaceutical compositions containing them |
| SE8704248D0 (sv) | 1987-10-30 | 1987-10-30 | Haessle Ab | Medical use |
| JP2643274B2 (ja) | 1988-04-08 | 1997-08-20 | 三菱化学株式会社 | イミダゾ〔１，２−ａ〕ピリジン誘導体 |
| US5593993A (en) | 1991-08-02 | 1997-01-14 | Medivir Ab | Method for inhibition of HIV related viruses |
| FR2714907B1 (fr) | 1994-01-07 | 1996-03-29 | Union Pharma Scient Appl | Nouveaux dérivés de l'Adénosine, leurs procédés de préparation, compositions pharmaceutiques les contenant. |
| TW385308B (en) | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
| JPH11505524A (ja) | 1995-05-01 | 1999-05-21 | 藤沢薬品工業株式会社 | イミダゾ１，２−ａピリジンおよびイミダゾ１，２−ａピリデジン誘導体、および骨吸収阻害剤としてのその用途 |
| CA2196263C (en) | 1996-02-09 | 2004-10-26 | Barry Jackson | Process for the preparation of 4-oxoimidazolinium salts |
| EP0802192A1 (de) | 1996-04-17 | 1997-10-22 | Bayer Ag | Heterocyclisch-substituierte Phenylglycinolamide mit antiatherosklerotischer Wirkung und Verfahren zu ihrer Herstellung |
| DE19642255A1 (de) * | 1996-10-14 | 1998-04-16 | Bayer Ag | Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten |
| US6403588B1 (en) | 2000-04-27 | 2002-06-11 | Yamanouchi Pharmaceutical Co., Ltd. | Imidazopyridine derivatives |
| CA2407573C (en) | 2000-04-27 | 2011-09-13 | Yamanouchi Pharmaceutical Co. Ltd. | Imidazopyridine derivatives |
| DE60303810D1 (de) * | 2002-09-01 | 2006-04-27 | Univ St Louis | Kontrollierte bakterielle lyse zur verabreichung von dna vakzinvektoren und impfantigen |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| KR20070045254A (ko) | 2004-08-02 | 2007-05-02 | 슈바르츠 파르마 악티엔게젤샤프트 | 인돌리진 카르복사미드 및 그 아자 및 디아자유도체 |
| GB0508992D0 (en) | 2005-05-03 | 2005-06-08 | Novartis Ag | Organic compounds |
| DK1902026T3 (da) | 2005-06-24 | 2010-04-26 | Lilly Co Eli | Tetrahydrocarbazol-derivater, der kan anvendes som androgen-receptor-modulatorer (SARM) |
| GB0514203D0 (en) | 2005-07-11 | 2005-08-17 | Novartis Ag | Organic compounds |
| PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| KR101118410B1 (ko) | 2006-10-19 | 2012-04-23 | 에프. 호프만-라 로슈 아게 | 당뇨병을 위한 11베타-에이치에스디1 억제제로서의 이미다졸론 및 이미다졸리딘온 유도체 |
| DE102006054562A1 (de) | 2006-11-20 | 2008-05-21 | Bayer Healthcare Ag | Verfahren zum Nachweis von Pyrophosphat mit Biolumineszenz Detektion |
| JP2010513495A (ja) | 2006-12-20 | 2010-04-30 | シェーリング コーポレイション | 新規なｊｎｋ阻害剤 |
| WO2008134553A1 (en) | 2007-04-26 | 2008-11-06 | Xenon Pharmaceuticals Inc. | Methods of using bicyclic compounds in treating sodium channel-mediated diseases |
| US8198449B2 (en) | 2008-09-11 | 2012-06-12 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| AU2011229423B2 (en) | 2010-03-18 | 2015-12-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Anti-infective compounds |
| DE102010020553A1 (de) | 2010-05-14 | 2011-11-17 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 8-Alkoxy-2-aminotetralin-Derivate und ihre Verwendung |
| EP2575473B1 (en) | 2010-05-27 | 2016-01-20 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| CA2803688A1 (en) | 2010-06-25 | 2011-12-29 | Bayer Intellectual Property Gmbh | Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes |
| US9029389B2 (en) | 2011-04-21 | 2015-05-12 | Institut Pasteur Korea | Anti-inflammation compounds |
| EP2716642B1 (en) | 2011-05-30 | 2016-07-20 | Astellas Pharma Inc. | Imidazopyridine compound |
| US8778964B2 (en) * | 2012-11-05 | 2014-07-15 | Bayer Pharma Aktiengesellschaft | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use |
| US9624214B2 (en) | 2012-11-05 | 2017-04-18 | Bayer Pharma Aktiengesellschaft | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
| US8796305B2 (en) * | 2012-11-05 | 2014-08-05 | Bayer Pharma Aktiengesellschaft | Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
| US9126998B2 (en) * | 2012-11-05 | 2015-09-08 | Bayer Pharma AG | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
| WO2014084312A1 (ja) | 2012-11-30 | 2014-06-05 | アステラス製薬株式会社 | イミダゾピリジン化合物 |
| CA2914100A1 (en) | 2013-06-04 | 2014-12-11 | Bayer Pharma Aktiengesellschaft | 3-aryl-substituted imidazo[1,2-a]pyridines and the use thereof |
| UY35693A (es) | 2013-08-08 | 2015-02-27 | Bayer Pharma AG | Pirazolo[1,5-a]piridin-3-carboxamidas sustituidas y su uso |
| EP3030564A1 (de) | 2013-08-08 | 2016-06-15 | Bayer Pharma Aktiengesellschaft | Substituierte imidazo[1,2-a]pyrazincarboxamide und ihre verwendung |
| WO2015082411A1 (de) | 2013-12-05 | 2015-06-11 | Bayer Pharma Aktiengesellschaft | Aryl- und hetaryl-substituierte imidazo[1,2-a]pyridin-3-carboxamide und ihre verwendung |
| US9688699B2 (en) | 2014-02-19 | 2017-06-27 | Bayer Pharma Aktiengesellschaft | 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines |
| CA2943005A1 (en) | 2014-03-21 | 2015-09-24 | Bayer Pharma Aktiengesellschaft | Cyano-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
| JP2017508811A (ja) | 2014-03-21 | 2017-03-30 | バイエル・ファルマ・アクティエンゲゼルシャフト | 置換イミダゾ［１，２−ａ］ピリジンカルボキサミドおよびその使用 |
| EP3137464A1 (de) | 2014-05-02 | 2017-03-08 | Bayer Pharma Aktiengesellschaft | Imidazo[1,2-a]pyridine als stimulatoren der löslichen guanylatcyclase zur behandlung von kardiovaskulären erkrankungen |
| CA2947387A1 (en) | 2014-05-02 | 2015-11-05 | Bayer Pharma Aktiengesellschaft | Imidazo[1,2-a]pyridines as soluble guanylate cyclase stimulators for the treatment of cardiovascular diseases |
-
2013
- 2013-11-01 US US14/070,180 patent/US9624214B2/en active Active
- 2013-11-04 TW TW102139893A patent/TWI630206B/zh not_active IP Right Cessation
- 2013-11-04 EP EP17168254.5A patent/EP3272749A1/de not_active Withdrawn
- 2013-11-04 SG SG10201703724UA patent/SG10201703724UA/en unknown
- 2013-11-04 JO JOP/2013/0318A patent/JO3397B1/ar active
- 2013-11-04 RS RS20170755A patent/RS56314B1/sr unknown
- 2013-11-04 SI SI201330709T patent/SI2914594T1/sl unknown
- 2013-11-04 PT PT137858692T patent/PT2914594T/pt unknown
- 2013-11-04 CN CN201380069254.2A patent/CN104981470B/zh active Active
- 2013-11-04 WO PCT/EP2013/072891 patent/WO2014068099A1/de not_active Ceased
- 2013-11-04 MY MYPI2015701401A patent/MY192724A/en unknown
- 2013-11-04 JP JP2015541088A patent/JP6423796B2/ja active Active
- 2013-11-04 MX MX2015005610A patent/MX363984B/es active IP Right Grant
- 2013-11-04 NZ NZ706728A patent/NZ706728A/en unknown
- 2013-11-04 ME MEP-2017-164A patent/ME02811B/me unknown
- 2013-11-04 PL PL13785869T patent/PL2914594T3/pl unknown
- 2013-11-04 SG SG11201502729XA patent/SG11201502729XA/en unknown
- 2013-11-04 AP AP2015008411A patent/AP2015008411A0/xx unknown
- 2013-11-04 KR KR1020157014608A patent/KR102122779B1/ko active Active
- 2013-11-04 PE PE2015000583A patent/PE20150883A1/es unknown
- 2013-11-04 HU HUE13785869A patent/HUE035408T2/en unknown
- 2013-11-04 BR BR112015010072-4A patent/BR112015010072B1/pt active IP Right Grant
- 2013-11-04 UA UAA201505433A patent/UA115887C2/uk unknown
- 2013-11-04 HR HRP20171179TT patent/HRP20171179T1/hr unknown
- 2013-11-04 ES ES13785869.2T patent/ES2635412T3/es active Active
- 2013-11-04 LT LTEP13785869.2T patent/LT2914594T/lt unknown
- 2013-11-04 US US14/440,509 patent/US20150274719A1/en not_active Abandoned
- 2013-11-04 EA EA201590870A patent/EA033626B1/ru not_active IP Right Cessation
- 2013-11-04 AU AU2013340726A patent/AU2013340726B2/en active Active
- 2013-11-04 EP EP13785869.2A patent/EP2914594B1/de active Active
- 2013-11-04 DK DK13785869.2T patent/DK2914594T3/en active
- 2013-11-04 CA CA2890356A patent/CA2890356C/en active Active
- 2013-11-05 AR ARP130104043A patent/AR093364A1/es active IP Right Grant
- 2013-11-05 UY UY0001035115A patent/UY35115A/es not_active Application Discontinuation
-
2015
- 2015-04-28 IL IL238493A patent/IL238493B/en active IP Right Grant
- 2015-05-01 DO DO2015000099A patent/DOP2015000099A/es unknown
- 2015-05-04 TN TNP2015000169A patent/TN2015000169A1/fr unknown
- 2015-05-04 GT GT201500105A patent/GT201500105A/es unknown
- 2015-05-04 PH PH12015500988A patent/PH12015500988B1/en unknown
- 2015-05-04 CL CL2015001163A patent/CL2015001163A1/es unknown
- 2015-05-05 EC ECIEPI201517505A patent/ECSP15017505A/es unknown
- 2015-05-05 CR CR20150232A patent/CR20150232A/es unknown
- 2015-05-05 SV SV2015004969A patent/SV2015004969A/es unknown
- 2015-05-28 ZA ZA2015/03828A patent/ZA201503828B/en unknown
-
2017
- 2017-03-02 US US15/447,205 patent/US10052312B2/en active Active
-
2018
- 2018-07-02 US US16/025,087 patent/US10662185B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20150883A1 (es) | Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso | |
| GT201300137A (es) | Derivados de imidazo [1,2-b] piridazina e imidazo [4,5-b] piridina como inhibidores de jak | |
| SMT201600157B (it) | Composti di carbammoilpiridone policiclici e loro uso farmaceutico | |
| UY35652A (es) | Bencil-1h-pirazolo[3,4-b]piridinas y su uso | |
| IL239639A0 (en) | A modified spiropyrido {1,2-a} pyrazine derivative and its medicinal use as an HIV integrase inhibitor | |
| UY33503A (es) | Imidazo [1,2-a]pirimidinas y piridinas sustituidas | |
| BR112013030909A2 (pt) | compostos de imidazopiridina | |
| CO6950473A2 (es) | Novedosos derivados de purina y su uso en el tratamiento de enfermedades | |
| ECSP15001882A (es) | Ácidos 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso | |
| HUE046216T2 (hu) | 1H-pirazolo [3,4-b]piridin-származékok és terápiás alkalmazásuk | |
| SV2011004019A (es) | 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso | |
| UY33865A (es) | Derivados Heterocíclicos Novedosos y su Uso en el Tratamiento de Trastornos Neurológicos | |
| ECSP14013224A (es) | Pirimidinas anilladas sustituidas y uso de las mismas | |
| CR20120596A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
| UA115677C2 (uk) | ПОХІДНІ ПІРОЛО[3,2-d]ПІРИМІДИНУ ДЛЯ ЛІКУВАННЯ ВІРУСНИХ ІНФЕКЦІЙ ТА ІНШИХ ЗАХВОРЮВАНЬ | |
| CR20130617A (es) | Derivados de piridin-2(1h)-ona útiles como medicamentos para el tratamiento de trastornos mieloproliferativos, rechazo de trasplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias | |
| UY35693A (es) | Pirazolo[1,5-a]piridin-3-carboxamidas sustituidas y su uso | |
| MX2016015248A (es) | Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal. | |
| EA201491376A1 (ru) | Производные 1h-пирроло[2,3-b]пиридина и их применение в качестве ингибиторов киназы | |
| IL236170A0 (en) | 2,3-dihydro-h1-imidazo[a-1,2]pyrimidin-5-one and 1,2,3,4-tetrahydropyrimido[a-1,2]pyrimidin-6-one derivatives containing modified morpholine, their preparation and pharmaceutical use their | |
| CR20140513A (es) | Uracilos sustituidos bicíclicamente y uso de los mismos | |
| UY31922A (es) | Compuestos | |
| CL2015001342A1 (es) | Compuestos derivados de pirrolo[3,2-d]pirimidina; composicion farmaceutica y de vacuna que los comprende y el uso en el tratamiento de enfermedades alergicas y otras enfermedades inflamatorias, infecciosas y cancer. | |
| CL2015000039A1 (es) | Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis. | |
| NI201600047A (es) | Tienouracilcarboxamidas cíclicas y usos de las mismas |